Page last updated: 2024-10-17

bupropion and Acute Coronary Syndrome

bupropion has been researched along with Acute Coronary Syndrome in 7 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
" Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS patients are limited."9.15Bupropion for smoking cessation in patients with acute coronary syndrome. ( Chasid, M; Elitzur, Y; Lev, I; Lotan, C; Ouzan, E; Planer, D; Pugatsch, T; Rom, M; Sharon, N, 2011)
" We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)."8.89Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013)
"To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion."7.78Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012)
" We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD)."4.89Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. ( Eisenberg, MJ; Grandi, SM; Shimony, A, 2013)
"To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion."3.78Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Moiz, A1
Eisenberg, MJ3
Franck, C1
Filion, KB1
Grandi, SM1
Shimony, A1
Landau, J1
Ajani, AE1
Carney, RM1
Freedland, KE1
Planer, D1
Lev, I1
Elitzur, Y1
Sharon, N1
Ouzan, E1
Pugatsch, T1
Chasid, M1
Rom, M1
Lotan, C1
Svanström, H1
Pasternak, B1
Hviid, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial[NCT00794573]Phase 3302 participants (Actual)Interventional2009-09-30Completed
Mindfulness-Based Cognitive Therapy Delivered Via Group Videoconferencing for Acute Coronary Syndrome Patients With Elevated Depression Symptoms[NCT03878160]27 participants (Actual)Interventional2018-07-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 12, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Varenicline86
Placebo55

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 24, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Varenicline70
Placebo49

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 4, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Varenicline90
Placebo57

7-Day Point Prevalence Smoking Abstinence

7-day point prevalence abstinence at week 52, defined as self-reported abstinence in the past week and exhaled carbon monoxide ≤10 ppm (NCT00794573)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Varenicline59
Placebo44

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 12. (NCT00794573)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Varenicline66
Placebo45

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 24. (NCT00794573)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Varenicline53
Placebo39

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 4. (NCT00794573)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Varenicline78
Placebo49

Continuous Smoking Abstinence

Continuous abstinence, defined as self-reported abstinence since baseline and exhaled carbon monoxide ≤10 ppm at all follow-up visits up to and including week 52. (NCT00794573)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Varenicline46
Placebo32

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Varenicline115
Placebo93

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Varenicline99
Placebo84

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Varenicline130
Placebo113

Reduction in Daily Cigarette Consumption by 50% or Greater

(NCT00794573)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Varenicline85
Placebo75

Interpersonal Reactivity Index (IRI)

This is a 14-item scale that measures empathy. The scoring scale ranges from 0, does not describe me well, to 4, describes me very well. The score values range from 0-56, where high values represent higher levels of empathy and lower values represent lower levels of empathy. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview41
Women and Men, >2 Years, Individual Interview39
Women and Men, Lifetime History of ACS, Individual Interview45

Medical Outcomes Study - Specific Adherence Scale (MOS- SAS)

This is a 3-item scale that measures health behaviors. The scoring scale ranges from 1, none of the time, to 6, all of the time. The scoring values range from 3-18, where higher values represent good health behavior and lower values represent poor health behavior. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview11
Women and Men, >2 Years, Individual Interview10
Women and Men, Lifetime History of ACS, Individual Interview13

Patient Health Questionnaire-9 (PHQ-9)

This is a 9-item scale that measures depression. The scoring scale ranges from 0, not at all, to 3, nearly every day. The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview10.5
Women and Men, >2 Years, Individual Interview16
Women and Men, Lifetime History of ACS, Individual Interview1.5

Patient Reported Outcome Measurement Information System-Physical Function (PROMIS-29-PF)

This is a 4-item scale that measures and evaluates physical health. The scoring scale ranges from 5, without any difficulty, to 1, unable to do. The scoring values range from 4-20, where high values represent good physical function and low values represent poor physical function. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview18
Women and Men, >2 Years, Individual Interview12
Women and Men, Lifetime History of ACS, Individual Interview20

Perceived Stress Scale-4 (PSS-4)

This is a 4-item scale that measures stress. The scoring scale ranges from 0,never, to 4, very often. The scale values range from 0-16 with higher values representing higher levels of individual stress and lower values representing lower levels of individual stress. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview12
Women and Men, >2 Years, Individual Interview14
Women and Men, Lifetime History of ACS, Individual Interview6

Positive Affect Negative Affect Schedule (PANAS)

This is a 20-question scale, composed of 2, 10-item scales that measure positive and negative affect. The scoring scale ranges from 1, very slightly or not at all, to 5, extremely. For this study, we will only use the positive affect sub-scale. The scale values for the positive affect sub-scale range from 10-50. Higher values on the positive affect scale represent higher levels of positive affect, whereas, lower values on the negative affect scale represent lower levels of positive affect. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview22
Women and Men, >2 Years, Individual Interview26
Women and Men, Lifetime History of ACS, Individual Interview34

Rumination Response Scale (RRS)

This is a 22-item scale that measures rumination. The scoring scale ranges from 1,almost never, to 4, almost always. The score values range from 22 to 88, where higher values represent higher levels of rumination and lower values represent lower levels of rumination. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview41
Women and Men, >2 Years, Individual Interview51.5
Women and Men, Lifetime History of ACS, Individual Interview31

Self-Other Four Immeasurables (SOFI) Scale

This is a 16-item scale that measures views toward the self and others. This measure consists of four sub-scales with four items each. The sub-scales measure positive views toward self, negative views toward self, positive views toward others, and negative views toward other. Only the positive-other sub-scale was used. The scoring scale ranges from 1, very slightly or not at all to 5, extremely, with sub-scale scores ranging from 4-20. Higher values represent higher levels of positive feelings toward others, and lower values represent lower levels of positive feelings toward others. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview15
Women and Men, >2 Years, Individual Interview12.5
Women and Men, Lifetime History of ACS, Individual Interview16

Short-Form-12 (SF-12)

This is a 12-item scale that measures health-related quality of life. The scoring scale from item 1 ranges from 1, excellent to 5, poor. The scoring scale for items 2 and 3 ranges from 1, limit you a lot to 3, not limit you at all. The scoring scale for questions 5-7 is represented by 1, yes or 2, no. The scoring scale for item 8 ranges from 1, not at all, to 5, extremely. The scoring scale for items 9-11 ranges from 1, all of the time, to 6, none of the time. The scoring scale for item 12 ranges from 1, all of the time to 5, none of the time. The total scoring values range from 12- 47, where higher values represent a higher quality of life and lower values represent a lower quality of life. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview26
Women and Men, >2 Years, Individual Interview22
Women and Men, Lifetime History of ACS, Individual Interview40

Five Factor Mindfulness Questionnaire- 15 Item (FFMQ-15)

This is a 15-item measure that measures mindfulness. This scale has five sub-scales: observing, describing, acting with awareness, accepting without judgment, and non-reactivity. The scoring scale ranges from 1, never or very rarely true to 5, very often or always true. Scale values range from 3-15 for each sub-scale, with higher values representing greater levels of individual mindfulness and lower values representing lowers levels of individual mindfulness. There is no total score for the measure; only individual sub-scales are reported. Data collection for this measurement is cross-sectional, and is collected during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

,,
Interventionunits on a scale (Median)
ObservingDescribingActing with awarenessAccepting without judgmentNonreactivity
Women and Men, <2 Years, Individual Interview811111111
Women and Men, >2 Years, Individual Interview99989.5
Women and Men, Lifetime History of ACS, Individual Interview1013101414

Number of Participants Reporting Changes After ACS

This portion of the individual interview will focus on exploring changes experienced after an ACS, such as psychosocial changes and health behavior changes. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Positive health behavior changesAdaptive perspectivesEmotional improvementsSocial improvementsActivity limitationsNegative physical symptomsEmotional problemsSocial problemsHealth behavior challenges
Women and Men, <2 Years, Individual Interview310155332
Women and Men, >2 Years, Individual Interview301078825
Women and Men, Lifetime History of ACS, Individual Interview1051546640

Number of Participants With Perspectives on Blood Spot Data Collection

This portion of the individual interview will focus on exploring ACS patients who had perspectives on participating in a remote dried blood spot procedure. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The criteria used to determine the outcome measure is the number of participants upon interview who reported any type of perspective on participating in a remote dried blood spot procedure (self-collection of dried blood spot via finger-prick). Please note that the number of perspectives reported for each theme can exceed the number of people per group because each participant reported multiple perspectives (e.g., both pros and cons of videoconferencing). (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to complete DBSWould need trainingWould want more information about the rationale
Women and Men, <2 Years, Individual Interview525
Women and Men, >2 Years, Individual Interview754
Women and Men, Lifetime History of ACS, Individual Interview826

Number of Participants With Perspectives on MBCT

This portion of the individual interview will focus on exploring patients' perspectives toward an MBCT treatment approach. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to get helpWilling to participate in a group programPositive reaction to mindfulness
Women and Men, <2 Years, Individual Interview334
Women and Men, >2 Years, Individual Interview867
Women and Men, Lifetime History of ACS, Individual Interview887

Number of Participants With Perspectives on Videoconferencing

This portion of the individual interview will focus on exploring perspectives regarding videoconferencing intervention delivery. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. Identified themes are reported, and the criteria used to determine the outcome measure is the number of participants upon interview who reported expressed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to try videoconferencingLogistical benefitsSocial benefitsTechnology limitationsSocial limitations
Women and Men, <2 Years, Individual Interview35222
Women and Men, >2 Years, Individual Interview75151
Women and Men, Lifetime History of ACS, Individual Interview87124

Reviews

3 reviews available for bupropion and Acute Coronary Syndrome

ArticleYear
Smoking Cessation in Patients With Acute Coronary Syndrome.
    The American journal of cardiology, 2018, 05-01, Volume: 121, Issue:9

    Topics: Acute Coronary Syndrome; Behavior Therapy; Bupropion; Cardiac Rehabilitation; Counseling; Electronic

2018
Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:12

    Topics: Acute Coronary Syndrome; Adult; Aged; Bupropion; Cardiovascular Diseases; Female; Follow-Up Studies;

2013
Treatment-resistant depression and mortality after acute coronary syndrome.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Acute Coronary Syndrome; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Therapy;

2009

Trials

1 trial available for bupropion and Acute Coronary Syndrome

ArticleYear
Bupropion for smoking cessation in patients with acute coronary syndrome.
    Archives of internal medicine, 2011, Jun-27, Volume: 171, Issue:12

    Topics: Acute Coronary Syndrome; Bupropion; Counseling; Dopamine Uptake Inhibitors; Double-Blind Method; Fem

2011

Other Studies

3 other studies available for bupropion and Acute Coronary Syndrome

ArticleYear
Initiation of Varenicline in People Hospitalized for Acute Coronary Syndrome Who Smoke.
    Circulation, 2023, 06-20, Volume: 147, Issue:25

    Topics: Acute Coronary Syndrome; Benzazepines; Bupropion; Cognition; Humans; Quinoxalines; Smoking; Smoking

2023
Bupropion and bradycardia.
    The Medical journal of Australia, 2008, Aug-04, Volume: 189, Issue:3

    Topics: Acute Coronary Syndrome; Adrenergic Agents; Anti-Arrhythmia Agents; Atropine; Bradycardia; Bupropion

2008
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
    BMJ (Clinical research ed.), 2012, Nov-08, Volume: 345

    Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Dise

2012